Trump's December 2025 executive order directed Attorney General Pam Bondi to expedite moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the DEA's May 2024 proposed rule following HHS recommendations, yet no final rule has issued amid administrative reviews and over 42,000 public comments. Recent pressure mounted with Democratic Rep. Steve Cohen's letter three days ago to Bondi and DEA Administrator Terry Cole seeking a timeline update, while Trump advisors express frustration over delays, hinting at potential leadership changes. Congressional opposition softened as 31 of 53 Senate Republicans skipped a blocking letter, clearing procedural hurdles, though trader consensus reflects persistent uncertainty in the rulemaking process absent a firm publication date.
Resumen experimental generado por IA con datos de Polymarket · Actualizado$279,493 Vol.
Mar 31, 2026
31 de marzo
<1%
30 de junio
28%
31 de diciembre
41%
$279,493 Vol.
31 de marzo
$262,210 Vol.
<1%
30 de junio
$10,862 Vol.
28%
31 de diciembre
$6,422 Vol.
41%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Trump's December 2025 executive order directed Attorney General Pam Bondi to expedite moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the DEA's May 2024 proposed rule following HHS recommendations, yet no final rule has issued amid administrative reviews and over 42,000 public comments. Recent pressure mounted with Democratic Rep. Steve Cohen's letter three days ago to Bondi and DEA Administrator Terry Cole seeking a timeline update, while Trump advisors express frustration over delays, hinting at potential leadership changes. Congressional opposition softened as 31 of 53 Senate Republicans skipped a blocking letter, clearing procedural hurdles, though trader consensus reflects persistent uncertainty in the rulemaking process absent a firm publication date.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado abierto: Nov 5, 2025, 2:57 PM ET
Volumen
$279,493Fecha de finalización
Mar 31, 2026Mercado abierto
Nov 5, 2025, 2:57 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Trump's December 2025 executive order directed Attorney General Pam Bondi to expedite moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the DEA's May 2024 proposed rule following HHS recommendations, yet no final rule has issued amid administrative reviews and over 42,000 public comments. Recent pressure mounted with Democratic Rep. Steve Cohen's letter three days ago to Bondi and DEA Administrator Terry Cole seeking a timeline update, while Trump advisors express frustration over delays, hinting at potential leadership changes. Congressional opposition softened as 31 of 53 Senate Republicans skipped a blocking letter, clearing procedural hurdles, though trader consensus reflects persistent uncertainty in the rulemaking process absent a firm publication date.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$279,493Fecha de finalización
Mar 31, 2026Mercado abierto
Nov 5, 2025, 2:57 PM ETResolver
0x65070BE91...Trump's December 2025 executive order directed Attorney General Pam Bondi to expedite moving cannabis from Schedule I to Schedule III under the Controlled Substances Act, building on the DEA's May 2024 proposed rule following HHS recommendations, yet no final rule has issued amid administrative reviews and over 42,000 public comments. Recent pressure mounted with Democratic Rep. Steve Cohen's letter three days ago to Bondi and DEA Administrator Terry Cole seeking a timeline update, while Trump advisors express frustration over delays, hinting at potential leadership changes. Congressional opposition softened as 31 of 53 Senate Republicans skipped a blocking letter, clearing procedural hurdles, though trader consensus reflects persistent uncertainty in the rulemaking process absent a firm publication date.
Resumen experimental generado por IA con datos de Polymarket · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes